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Abstract
Aims/hypothesis The study aimed to assess the associations of maternal early-pregnancy blood glucose levels with fetal growth
throughout pregnancy and the risks of adverse birth outcomes.
Methods In a population-based prospective cohort study among 6116 pregnant women, maternal non-fasting glucose levels were
measured in blood plasma at a median 13.2 weeks of gestation (95% range 9.6–17.6).We measured fetal growth by ultrasound in
each pregnancy period.We obtained information about birth outcomes frommedical records andmaternal sociodemographic and
lifestyle factors from questionnaires.
Results Higher maternal early-pregnancy non-fasting glucose levels were associated with altered fetal growth patterns,
characterised by decreased fetal growth rates in mid-pregnancy and increased fetal growth rates from late pregnancy onwards,
resulting in an increased length and weight at birth (p ≤0.05 for all). A weaker association of maternal early-pregnancy non-
fasting glucose levels with fetal head circumference growth rates was present. Higher maternal early-pregnancy non-fasting
glucose levels were also associated with an increased risk of delivering a large-for-gestational-age infant, but decreased risk of
delivering a small-for-gestational-age infant (OR 1.28 [95% CI 1.16, 1.41], OR 0.88 [95% CI 0.79, 0.98] per mmol/l increase in
maternal early-pregnancy non-fasting glucose levels, respectively). These associations were not explained by maternal
sociodemographic factors, lifestyle factors or BMI. Maternal early-pregnancy non-fasting glucose levels were not associated
with preterm birth or delivery complications.
Conclusions/interpretation Higher maternal early-pregnancy non-fasting glucose levels are associated with decreased fetal
growth rates in mid-pregnancy and increased fetal growth rates from late pregnancy onwards, and an increased risk of delivering
a large-for-gestational-age infant. Future preventive strategies need to focus on screening for an impaired maternal glucose
metabolism from preconception and early pregnancy onwards to improve birth outcomes.
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Abbreviations
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Introduction
Gestational diabetes mellitus (GDM) complicates up to 17%
of pregnancies and is a major risk factor for maternal and fetal
perinatal complications [1–3]. Recent studies suggest that
these associations are also present for higher maternal glucose
levels below the threshold of GDM [4–6]. A meta-analysis of
25 prospective studies showed that higher maternal glucose
levels in mid-pregnancy and late pregnancy are related to in-
creased risks of perinatal complications [7].
Accumulating evidence suggests that early pregnancy is a
critical period for the effects of adverse exposures on embry-
onic and placental development [8, 9]. Little is known, how-
ever, about the direct effects of an impaired maternal glucose
metabolism from early pregnancy onwards on fetal growth
and the risks of adverse birth outcomes in both diabetic and
non-diabetic pregnant women [3]. Among women with
GDM, fetal growth may already be abnormal preceding this
diagnosis. However, results are inconsistent and difficult to
interpret as maternal glucose levels before the diagnosis of
GDM are unknown [10, 11]. We hypothesised that a maternal
glucose metabolism already impaired in early pregnancy
affects embryonic and placental development, subsequently
leading to altered fetal growth and increased risks of adverse
birth outcomes [2, 3, 12, 13]. Insight into the influence of
maternal blood glucose levels from early pregnancy onwards
on fetal development is important, as maternal blood glucose
levels offer a major target for potential future interventions.
Therefore, in a population-based prospective cohort study
among 6116 pregnant women, we examined whether maternal
early-pregnancy non-fasting glucose levels across the full
range, and not limited to diagnostic thresholds, are associated
with fetal growth in each pregnancy period and with the risks of
adverse birth outcomes. To obtain further insight into the cau-
sality of these associations, we additionally explored whether
these associations are explained by maternal sociodemographic
factors or lifestyle factors.
Methods
Study design This study was embedded in the Generation R
Study, a population-based prospective cohort study from early
pregnancy onwards in Rotterdam, the Netherlands [14]. The
study was approved by the local Medical Ethical Committee
(MEC 198.782/2001/31). Written informed consent was ob-
tained from all participating women. All pregnant women,
who were resident in the study area at their delivery date, were
enrolled between 2001 and 2005. Translated information
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packages and questionnaires were available for recruitment of
different ethnicities. The enrolment procedure has been de-
scribed in detail previously [15]. Response rate at birth was
61% [16]. In total, 8879 women were enrolled during preg-
nancy, of whom 6186 had measurements of glucose levels
available. We excluded pregnancies not leading to singleton
live births (n = 70). The population for analyses comprised
6116 women (Fig. 1). Since only a small number of woman
(n = 24) had pre-gestational diabetes mellitus, these individ-
uals were included in the analyses. A sensitivity analysis ex-
cluding women with pre-gestational diabetes mellitus was
performed.
Maternal glucose metabolism Blood samples were collected
once in early pregnancy at 13.2medianweeks’ gestation (95%
range 9.6–17.6). After 30 min of fasting, venous blood sam-
ples were collected from pregnant women by research nurses
and temporally stored at room temperature. We considered the
30 min fasting samples non-fasting samples. This time-
interval was chosen because of the design of our study, in
which it was not possible to obtain fasting samples from all
pregnant women. At least every 3 h, blood samples were
transported to a dedicated laboratory facility of the regional
laboratory in Rotterdam, the Netherlands (Star-MDC), for fur-
ther processing and storage [17]. Glucose (mmol/l) is an en-
zymatic quantity and was measured with the c702 module on
a Cobas 8000 analyser. Insulin (pmol/l) was measured with
electrochemiluminescence immunoassay on a Cobas e411
analyser. Quality control samples demonstrated intra- and
inter-assay CVs of 1.30% and 2.50%, respectively. We con-
structed maternal early-pregnancy non-fasting glucose and in-
sulin SD scores (SDSs).
Information on pre-gestational diabetes mellitus was ob-
tained from self-reported questionnaires and on GDM from
Mothers prenatally enrolled in study
(N = 8879)
Total population for analysis (N = 6116)
Data on mid-pregnancy fetal growth:
Head circumference (n = 5873)
Abdominal circumference (n = 5886)
Femur length (n = 5886)
Estimated fetal weight (n = 5862)
Data on late-pregnancy fetal growth:
Head circumference (n = 5848)
Abdominal circumference (n = 5878)
Femur length (n = 5890)
Estimated fetal weight (n = 5869)
Data on birth outcomes:
Head circumference at birth (n = 3350)
Length at birth (n = 3927)
Weight at birth (n = 6078)
Excluded (n = 70)
No data on singleton live-birth
pregnancy outcome
Excluded (n = 2693)
No data on early-pregnancy
maternal glucose metabolism
Mothers with available information 
on maternal early-pregnancy 
glucose metabolism (n = 6186) 
Fig. 1 Study participant flow chart
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medical records after delivery. GDMwas diagnosed by a com-
munity midwife or an obstetrician according to Dutch mid-
wifery and obstetric guidelines using the following criteria:
either a random glucose level >11.0 mmol/l, a fasting glucose
≥7.0 mmol/l or a fasting glucose between 6.1 and 6.9 mmol/l
with a subsequent abnormal GTT [18]. In clinical practice and
for this study sample, an abnormal GTT was defined as a
glucose level greater than 7.8 mmol/l after glucose intake.
Fetal growth patterns and adverse birth outcomes Fetal ul-
trasound examinations were carried out in two dedicated re-
search centres in early pregnancy (13.2 median weeks’ gesta-
tion [95% range 9.6–17.6]), mid-pregnancy (20.5 median
weeks’ gestation [95% range 18.7–23.1]) and late pregnancy
(30.3 median weeks’ gestation [95% range 28.5–32.8]). In
early pregnancy we used crown–rump length to assess fetal
growth only in mothers with a known and reliable first day of
the last menstrual period, a regular menstrual cycle of 28 days
(range 24–32 days) and who had fetal crown–rump length
measured between a gestational age of 10 weeks 0 days and
13 weeks 6 days (n = 1470), as described previously [19]. The
first day of the last menstrual period was obtained from the
referring letter from the community midwife or hospital. This
date was confirmed with the participants at the ultrasound visit
and additional information on the regularity and duration of
the menstrual cycle was obtained [19]. For mothers without
this information, gestational age was established by early-
pregnancy fetal ultrasound examination. This strategy was
performed because of the large number of mothers who did
not know the exact date of their last menstrual period or who
had irregular menstrual cycles [20]. Subsequently, in mid-
pregnancy and late pregnancy, we measured fetal head cir-
cumference, abdominal circumference and femur length to
the nearest millimetre using standardised ultrasound proce-
dures. Estimated fetal weight was subsequently calculated
using the formula of Hadlock et al [21]. Longitudinal growth
curves and gestational-age-adjusted SDSs were constructed
for all fetal biometry measurements [20]. These gestational-
age-adjusted SDSs were based on reference growth curves
from the whole study population and represent the equivalent
of z scores [20].
Information about offspring sex, gestational age, weight,
length and head circumference at birth was obtained from
medical records [14]. Since head circumference and length
were not routinely measured at birth, fewer measurements
were available (n = 3350 for head circumference and n =
3927 for length at birth). Gestational-age-adjusted SDSs for
head circumference, length and weight at birth were construct-
ed using North European growth standards as the reference
growth curve and represent the equivalent of z scores [22].
Small-for-gestational-age and large-for-gestational-age at
birth were defined as the lowest and highest 10 percentiles
of gestational age- and sex-adjusted birthweight using North
European growth standards [22]. Preterm birth was defined as
a gestational age at birth <37 weeks. Information on delivery
complications, Caesarean delivery and vacuum extraction,
was collected from medical records.
Covariates Information on maternal age, pre-pregnancy
weight, educational level, ethnicity, parity and folic acid sup-
plements use was obtained at enrolment by questionnaires
[14]. Height and weight, both without shoes and heavy cloth-
ing, were measured at enrolment. Pre-pregnancy BMI was
calculated (self-reported pre-pregnancy weight in kilograms
divided by height measured at first study visit in metres
squared). Information about smoking and alcohol consump-
tion was assessed by questionnaires. We dichotomised both
variables; women were classified as ‘yes’ if they consumed
alcohol and smoked until pregnancy was known and if they
continued to drink alcohol and smoke throughout pregnancy.
Information on total daily energy intake was obtained by a
food frequency questionnaire in early pregnancy [14].
Statistical analysis First, we conducted a non-response analy-
sis to compare characteristics of women with and without
glucose measurements available. Normally distributed data
were presented as mean with SD; non-normally distributed
data were presented as median with 95% range (i.e. the 2.5th
to 97.5th percentile).
Second, we assessed the associations of maternal early-
pregnancy non-fasting glucose levels with repeatedly mea-
sured fetal biometry measurements to assess fetal growth pat-
terns using unbalanced repeated measurement regression
models. These models take the correlation between repeated
measurements of the same individual into account and allow
for incomplete outcome data [23]. We included maternal
early-pregnancy non-fasting glucose levels in these models
as intercept and as interaction term with gestational age to
estimate fetal growth rates over time [23]. These analyses
were conducted without adjustment for covariates, which
most clearly reflects clinical practice [7].
Third, we examined the associations of maternal early-
pregnancy non-fasting glucose levels with detailed fetal biom-
etry measurements in gestational-age-adjusted SDS in each
pregnancy period using linear regression models. Analyses
were repeated using fetal biometry measurements in absolute
values. For these analyses, we constructed different models to
explore whether these observed associations were explained
by maternal sociodemographic and lifestyle factors: a basic
model (adjusted for gestational age at assessment), a maternal
ethnicity model (basic model additionally adjusted for ethnic-
ity), a maternal pregnancy-related factors model (maternal
ethnicity model additionally adjusted for maternal age, parity,
educational level, daily total energy intake, smoking, alcohol
consumption and folic acid supplement use) and a maternal
BMI model (maternal pregnancy-related factors model
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additionally adjusted for maternal pre-pregnancy BMI).
Included covariates were based on previous studies, strong
correlations with maternal glucose levels, risk of GDM and
fetal biometry measurements, and changes in effect estimates
of >10% [2, 3].
Fourth, we assessed the associations of maternal early-
pregnancy non-fasting glucose levels with the risks of adverse
birth outcomes using multiple logistic regression models
using the same adjustment models. We explored whether as-
sociations were non-linear by performing quintiles analyses
and adding a quadratic term to the original model. However,
for all analyses, a linear model had the best fit. Since only
seven women had glucose levels of >7.8 mmol/l and only
62 women developed GDM, we were unable to explore the
effects of these clinical categories on fetal growth and adverse
birth outcomes. We tested but did not observe statistical inter-
actions between maternal ethnicity or pre-pregnancy BMI and
maternal early-pregnancy non-fasting glucose levels for the
associations with fetal biometry measurements and with ad-
verse birth outcomes [2, 3, 10, 11].
As a sensitivity analysis, analyses were repeated using ma-
ternal early-pregnancy non-fasting insulin levels. To enable
comparison of effect sizes for the associations of different
measures of maternal early-pregnancy glucose metabolism
with fetal growth and birth outcomes, these sensitivity analy-
ses were performed using maternal early-pregnancy non-
fasting glucose and insulin levels in SDSs. In addition, we
explored whether our observed associations were affected by
specific subgroups. We performed five additional sensitivity
analyses for the associations of maternal early-pregnancy non-
fasting glucose levels with fetal biometry measurements in
each pregnancy period: (1) excluding women with pre-
gestational diabetes mellitus (n = 24); (2) excluding women
with GDM (n = 62); (3) among women of Dutch ethnicity
only; (4) among women included in early pregnancy only
(before 14 weeks’ gestation); and (5) among term births only.
Missing data of covariates were imputed using multiple
imputation. Five imputed datasets were created and analysed
together. Repeated measurement analyses were performed
using the Statistical Analysis System version 9.4 (SAS
Institute, Cary, NC, USA; Proc Mixed module). All other
analyses were performed using the Statistical Package of
Social Sciences version 24.0 for Windows (SPSS, Chicago,
IL, USA).
Results
Population characteristics are shown in Table 1. Fetal growth
characteristics of the study population are shown in Table 2.
Non-response analyses showed that women without glucose
measurements had a higher BMI, had a lower level of educa-
tional attainment, were of non-European descent and used
Table 1 Maternal and birth characteristics of the study population
Characteristic Total group, N = 6116
Maternal characteristics
Age, years 29.8 ± 5.1
Height, cm 167.5 ± 7.4
Pre-pregnancy weight, kg 64.0 (48.0–99.7)
Pre-pregnancy BMI, kg/m2 22.6 (18.0–34.7)
Gestational age at intake, weeks 13.2 (9.6–17.6)
Parity (nulliparous) 3474 (57.3)
Ethnicity
Dutch 3083 (52.2)
European 496 (8.4)
Cape Verdean 245 (4.2)
Moroccan 353 (6.0)
Dutch Antillean 171 (2.9)
Surinamese 506 (8.6)
Turkish 474 (8.1)
Other 545 (9.3)
Education, higher 2550 (44.9)
Total energy intake, kJ 486 (134)
Folic acid use
No 1183 (25.3)
Start first 10 weeks 1491 (31.9)
Start periconceptional 1997 (42.8)
Smoking during pregnancy, continued 1012 (18.6)
Alcohol use during pregnancy, continued 2095 (39.0)
Gestational hypertensive disorders
Pre-eclampsia 127 (2.2)
Gestational hypertension 234 (4.1)
Glucose, mmol/l 4.4 ± 0.8
Insulin, pmol/l 114.6 (17.6–716.1)
Impaired glucose tolerance at intakea 17 (0.3)
Pre-gestational diabetes mellitus 24 (0.5)
GDM 62 (1.1)
Birth characteristics
Male 3100 (50.7)
Gestational age, weeks 40.1 (35.6–42.3)
Preterm birthb 310 (5.1)
Small for gestational agec 606 (10.0)
Large for gestational aged 606 (10.0)
Caesarean delivery 692 (14.5)
Vacuum extraction 774 (15.9)
Values are numbers (%), means ± SD or medians (95% range)
a Impaired glucose tolerance at intake is defined as >7.8 mmol/l in non-
fasting state
b Preterm birth is defined as <37 weeks’ gestation
c Small for gestational age is defined as <10th percentile of age- and sex-
adjusted birthweight
d Large for gestational age is defined as >90th percentile of age- and sex-
adjusted birthweight
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folic acid supplements less often (electronic supplementary
material [ESM] Table 1).
Maternal blood glucose levels and fetal growth Figure 2
shows that higher maternal early-pregnancy non-fasting glu-
cose levels were associated with increased rates of fetal length
and weight growth from late pregnancy onwards, resulting in
increased length and weight at birth (p value for interaction
with gestational age <0.05). Weaker effect estimates were ob-
served for the associations of maternal early-pregnancy non-
fasting glucose levels with rate of fetal head circumference
growth, but a significant interaction with gestational age was
also present (p value for interaction with gestational age
<0.05).
Figure 3 shows that maternal early-pregnancy non-fasting
glucose levels were not significantly associated with early-
pregnancy fetal crown–rump length. Higher maternal early-
pregnancy non-fasting glucose levels were associated with de-
creased mid-pregnancy fetal head circumference SDS and ab-
dominal circumference SDS (p ≤0.05 for both). The associa-
tion of higher maternal early-pregnancy non-fasting glucose
levels with decreased mid-pregnancy estimated fetal weight
SDS did not reach statistical significance (p = 0.10). No asso-
ciation with mid-pregnancy femur length was present.
However, higher maternal early-pregnancy non-fasting glu-
cose levels were associated with increased fetal head circum-
ference SDS, abdominal circumference SDS, femur length
SDS and estimated fetal weight SDS in late pregnancy, and
head circumference SDS, length SDS and weight SDS at birth
(p ≤0.05 for all). These associations were not explained by
adjustment for maternal ethnicity, or other maternal
pregnancy-related factors, but were partly attenuated after ad-
justment for maternal pre-pregnancy BMI (maternal ethnicity-
adjusted model is given in ESM Table 2). The strongest effect
estimate was present for birthweight (difference in birthweight
in the maternal pregnancy-related model: 0.07 SDS [95% CI
0.04, 0.10] per mmol/l increase in maternal early-pregnancy
non-fasting glucose levels; p ≤0.05). The associations of ma-
ternal early-pregnancy non-fasting glucose levels with
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Fig. 2 Differences in fetal growth rates per change in glucose levels. Data
are SDS values (95% CI) from repeated measurement regression models
that reflect the differences in gestational age-adjusted growth rates in SDS
of head circumference (circles), length (triangles) and weight (squares) at
mid-pregnancy, late pregnancy and at birth per 1 mmol/l change in ma-
ternal early-pregnancy glucose levels. As a measure of skeletal length
growth from mid-pregnancy onwards, we used fetal femur length SDS
in mid-pregnancy and late pregnancy and total body length SDS at birth
within the repeated measurements model. All fetal biometry measure-
ments for each pregnancy period were taken at the same time point.
The models were adjusted for gestational age at intake. p <0.05 for inter-
action with gestational age for all models
Table 2 Fetal growth characteristics of the study population
Fetal growth characteristic Total group, N = 6116
Mid-pregnancy
Gestational age, weeks 20.5 (18.7–23.1)
Head circumference, mm 179 ± 13.3
Abdominal circumference, mm 156 ± 13.7
Femur length, mm 33 ± 3.3
Estimated fetal weight, g 377 ± 83.9
Late pregnancy
Gestational age, weeks 30.3 (28.5–32.8)
Head circumference, mm 285 ± 12.2
Abdominal circumference, mm 264 ± 16.3
Femur length, mm 57 ± 8.7
Estimated fetal weight, g 1611 ± 251.0
Birth
Gestational age, weeks 40.1 (35.6–42.3)
Birth head circumference, cm 33.8 ± 1.7
Birth length, cm 50.2 ± 2.4
Birthweight, g 3418 ± 563
Values are means ± SD or medians (95% range)
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absolute values of fetal biometry measurements are given in
ESMTable 3 and showed similar findings to themain findings.
Per 1 mmol/l increase in maternal early-pregnancy non-fasting
glucose levels, birthweight increased by 25.4 g (95% CI 9.0,
41.8) in the maternal pregnancy-related model (p ≤0.05).
Impact of maternal early-pregnancy blood glucose levels on
adverse birth outcomes Independent of maternal
sociodemographic or lifestyle factors, higher maternal early-
pregnancy non-fasting glucose levels were associated with an
increased risk of delivering a large-for-gestational-age infant,
but with a decreased risk of delivering a small-for-gestational-
age infant (ORs 1.28 [95% CI 1.16, 1.41] and 0.88 [95% CI
0.79, 0.98] per mmol/l increase in maternal early-pregnancy
non-fasting glucose levels in the maternal pregnancy-related
model [p ≤0.05], respectively) (Table 3, and maternal
ethnicity-adjusted model is given in ESM Table 4). No signif-
icant associations were present for maternal early-pregnancy
non-fasting glucose levels with preterm birth, Caesarean de-
livery or vacuum extraction.
Sensitivity analyses The sensitivity analyses using maternal
early-pregnancy non-fasting insulin levels, instead ofmaternal
early-pregnancy non-fasting glucose levels, showed that ma-
ternal early-pregnancy non-fasting insulin levels were largely
similarly associated with fetal growth rates and fetal biometry
measurements in each pregnancy period (ESM Table 5, ESM
Figs 1 and 2). Based on comparison of the effect estimates per
SDS increase inmaternal early-pregnancy non-fasting glucose
and insulin levels, the strength of the associations with fetal
biometry measurements was also largely the same. Similar
results to the main findings were found when we excluded
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Fig. 3 Associations of maternal early-pregnancy glucose levels in mmol/l
with fetal biometry measurements (N = 6116). Data are SDS values (95%
CI) from linear regression models that reflect the differences in growth
characteristics in SDSs in (a) early pregnancy, (b) mid-pregnancy, (c) late
pregnancy and (d) at birth, per 1 mmol/l change in maternal early-preg-
nancy glucose levels. Analyses with crown–rump length were based on
subgroup analyses (n = 1470). Estimates are from multiple imputed data.
Squares show basic model: adjusted for gestational age at assessment.
Circles show maternal pregnancy-related factors model: basic model ad-
ditionally adjusted for maternal ethnicity, age, parity, educational level,
daily total energy intake, smoking, alcohol consumption and folic acid
supplement use. Triangles show BMI model: maternal pregnancy-related
factors model additionally adjusted for maternal pre-pregnancy BMI
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women with pre-gestational diabetes mellitus or GDM and
when we restricted our analyses to women of Dutch ethnicity
only, women included in early pregnancy only and among
term births only (ESM Table 6).
Discussion
We observed that maternal early-pregnancy blood glucose
levels across the full spectrum are associated with altered fetal
growth patterns, characterised by decreased fetal growth rates
in mid-pregnancy and increased fetal growth rates from late
pregnancy onwards, and an increased risk of delivering a
large-for-gestational-age infant. These associations were only
partly explained by maternal pre-pregnancy BMI, and not by
other maternal pregnancy-related factors.
Interpretation of main findings Maternal GDM and
hyperglycaemia diagnosed in the second half of pregnancy
are common andmajor risk factors for adverse birth outcomes.
It is likely that women who develop GDM or hyperglycaemia
later in pregnancy already have a suboptimal glucose metab-
olism preconceptionally or in early pregnancy, a critical period
for embryonic and placental development [10, 11]. Despite
well-known associations of maternal GDMwith adverse birth
outcomes, direct effects of a disturbed maternal glucose me-
tabolism from early pregnancy onwards on fetal growth re-
main unclear. Fetuses of women with pre-gestational type 1
and type 2 diabetes mellitus are at increased risk for
macrosomia at birth, but also for delayed growth during early
pregnancy. This latter association may be due to poor glucose
control already preconceptionally or very early in pregnancy
[24–27]. The role of maternal glucose metabolism in early
pregnancy in relation to fetal development and birth outcomes
is not clear in women without overt diabetes.
Among women with GDM, it has been suggested that fetal
growth is already abnormal preceding the diagnosis of GDM.
Results from a cohort study among 533 women showed that,
compared with those without GDM, those with GDM had
smaller fetuses until 24 weeks of gestation, followed by accel-
erated fetal growth in late pregnancy [11]. A study among
4069 pregnant women showed that fetuses of women with
GDM had increased abdominal circumference growth rates
between 20 and 28 weeks of gestation, with the strongest
effects among obese women [10]. Similarly, a prospective
study among 741 black African women showed increased
fetal abdominal circumference growth rates from mid-
pregnancy onwards in women with GDM compared with
those without GDM [28]. As maternal glucose levels before
the diagnosis of GDM were not known in these studies, these
findings are difficult to interpret in the context of the present
study results. We observed that among non-diabetic women,
higher maternal early-pregnancy non-fasting glucose levels
across the full range were associated with decreased fetal
growth rates in mid-pregnancy and increased fetal growth
rates from late pregnancy onwards resulting in larger size at
birth. These associations were independent of maternal eth-
nicity, a well-known risk factor for GDM and an important
determinant for fetal growth. Also, other maternal pregnancy-
related factors, including pre-pregnancy BMI, did not explain
the observed associations. When we assessed each pregnancy
period separately, we also observed that higher maternal early-
pregnancy non-fasting glucose levels tended to be associated
with smaller fetal biometry measurements in early pregnancy
and mid-pregnancy, although for some measurements there
was no significant association. Thus, our results suggest that
already among non-diabetic women, higher maternal early-
pregnancy non-fasting glucose levels within the normal range
are related to altered fetal growth patterns, characterised by
decreased fetal growth rates in mid-pregnancy and increased
fetal growth rates from late pregnancy onwards. The presence
of associations for all fetal biometry measurements suggests
that maternal early-pregnancy non-fasting glucose levels af-
fect both fetal fat development and skeletal growth.
Table 3 Associations of maternal early-pregnancy glucose levels with the risks of adverse birth outcomes
Maternal early-pregnancy
glucose levels (mmol/l)
Small for gestational
age at birth
Large for gestational
age at birth
Preterm birth Caesarean delivery Vacuum extraction
Basic modela 0.89 (0.80, 0.98)* 1.27 (1.16, 1.40)* 1.08 (0.95, 1.24) 1.12 (0.98, 1.27) 0.99 (0.90, 1.09)
Maternal pregnancy-related factors modelb 0.88 (0.79, 0.98)* 1.28 (1.16, 1.41)* 1.08 (0.94, 1.23) 1.11 (1.00, 1.23) 1.01 (0.91, 1.12)
BMI modelc 0.91 (0.82, 1.02) 1.21 (1.10, 1.34)* 1.06 (0.92, 1.21) 1.09 (0.99, 1.20) 1.01 (0.90, 1.12)
Values are ORs (95% CI) from logistic regression models that reflect the differences in risks of adverse birth outcomes per 1 mmol/l increase in maternal
early-pregnancy glucose levels. Estimates are from multiple imputed data
a Basic model adjusted for gestational age at assessment
bMaternal pregnancy-related factors model: basic model additionally adjusted for maternal ethnicity, age, parity, educational level, daily total energy
intake, smoking, alcohol consumption and folic acid supplement use
c BMI model: maternal pregnancy-related factors model, additionally adjusted for maternal pre-pregnancy BMI
*p <0.05
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Impaired maternal gestational glucose metabolism is a ma-
jor risk factor for delivering a large-for-gestational-age infant,
preterm birth and Caesarean delivery, with even stronger ef-
fects among overweight and obese women [2, 7, 29–32]. A
retrospective study among more than 6000 women showed
that higher maternal glucose levels at 9.5 weeks’ gestation
were associated with an increased risk of delivering a large-
for-gestational-age infant [3]. A case–control study among
2050 women with term deliveries observed an association of
maternal early-pregnancy glucose levels with delivering large-
for-gestational-age infants, independent of maternal BMI
[31]. A large cohort among 46,000 women showed that higher
maternal glucose levels between 10 and 24 weeks of gestation
were associated with an increased risk of spontaneous preterm
birth [33]. We observed that already a small increase in ma-
ternal early-pregnancy non-fasting glucose levels within the
normal range was related to an increased risk of delivering a
large-for-gestational-age infant, but a decreased risk of deliv-
ering a small-for-gestational-age infant. These associations
were independent of maternal pre-pregnancy BMI. BMI is a
measure of general adiposity, but does not provide any infor-
mation on more specific fat compartments, such as visceral fat
mass. Alterations in maternal visceral fat mass, which is more
metabolically active, might explain part of the observed asso-
ciations. In addition, our study population is a relatively lean
population. The effect of maternal pre-pregnancy BMI on the
observed associations might be stronger among more obese
populations. We did not observe associations for preterm
birth, Caesarean delivery or vacuum extraction. It seems likely
that associations of maternal early-pregnancy non-fasting glu-
cose levels with delivery complications are partly driven by
size at birth as well as other maternal characteristics, such as
maternal obesity. Even though we did observe that higher
maternal early-pregnancy non-fasting glucose levels were as-
sociated with an increased risk of a large-for-gestational-age
infant, the overall effect on birthweight in the full cohort was
relatively small. This may partly explain the lack of associa-
tions with the delivery complications. These associations may
be more apparent among higher-risk populations. Thus, our
findings suggest that in a non-diabetic population, non-fasting
glucose levels in early pregnancy already partly determine the
risk of delivering a large-for-gestational-age infant.
The mechanisms underlying associations of maternal glu-
cose metabolism with reduced fetal growth in the first half of
pregnancy and increased fetal growth thereafter are not
known. It has been suggested that impaired glucose control
during early pregnancy negatively affects placental develop-
ment, starting with impaired early placentation, which induces
placental insufficiency and thereby early fetal growth restric-
tion [11]. In response to the placental insufficiency, it has been
suggested that the fetus may induce maternal hyperglycaemia
to improve nutrient supply and growth during the second half
of pregnancy via placental signalling [11]. It has also been
hypothesised that hyperglycaemia in early pregnancy injures
the development of the yolk sac, which is of great importance
during the embryonic period, especially in nutrient transport
towards the embryo. This may lead to impaired embryonic
growth and development. When the yolk sac function is re-
placed by the placenta at the end of early pregnancy,
hyperglycaemia together with increased transfer of other nu-
trients could induce an intrauterine environment that stimu-
lates increased fetal adiposity and growth [2, 34].
Even though the observed effects for the associations of
maternal blood glucose levels with altered fetal growth pat-
terns and the risk of delivering a large-for-gestational-age in-
fant are relatively small, they are important from an
aetiological and preventive perspective. Importantly, we ob-
served the adverse effects of maternal blood glucose levels
across the full range of maternal early-pregnancy non-fasting
glucose levels and not only at the diagnostic thresholds of
impaired glucose metabolism. In addition, the observed asso-
ciations were not explained by maternal sociodemographic
factors or lifestyle factors, which suggests that potential intra-
uterine mechanismsmay be involved. Current clinical practice
is mainly focused on screening for GDM based on diagnostic
thresholds of maternal glucose levels from mid-pregnancy
onwards in higher-risk women. However, based on our find-
ings, altered fetal development can already occur among non-
diabetic women before mid-pregnancy, which is when screen-
ing for GDM and necessary interventions are currently imple-
mented. Recent RCTs, which are considered the gold standard
for studying causality, indicate that treatment of GDM and
maternal hyperglycaemia with lifestyle adaptations from
mid-pregnancy onwards leads to a decreased risk of adverse
birth outcomes compared with no treatment [35–37]. Based
on our findings, future RCTs should focus on glucose screen-
ing and treatment from preconception and early pregnancy
onwards to further improve pregnancy outcomes, among
higher-risk populations such as overweight and obese women
and possibly also among lower-risk populations. These stud-
ies should assess the effects of lifestyle interventions that keep
an adequate balance between reducingmaternal blood glucose
levels without inducing hypoglycaemia and preventing
hyperglycaemia. These interventional studies from precon-
ception and early pregnancy onwards will not only provide
important novel insights into the effectiveness of these inter-
ventions, but also into the causality of the observed associa-
tions of maternal early-pregnancy non-fasting glucose levels
with altered fetal growth and adverse birth outcomes.
Methodological considerations Major strengths of this study
are the population-based prospective design with a large sample
size with information on maternal blood glucose levels and fetal
growth throughout pregnancy. The response rate at baseline was
61%. The non-response at baseline would lead to biased effect
estimates if associations were different between those included
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and not included in the analyses, but this seems unlikely. We had
a relatively small number of cases of GDM, which indicates a
selection towards a non-diabetic population and might affect the
generalisability of our findings. The observed associations might
be stronger among higher-risk populations. Information on
GDM was obtained from medical records after delivery.
Accurate diagnosis of GDM is difficult. A fasting glucose greater
that 7.0mmol/l might also represent preexisting diabetes mellitus
and a fasting glucose between 6.1 and 6.9 mmol/l might also
represent impaired glucose tolerance, instead of GDM.
Unfortunately, in our study, glucose testing for diagnosis of
GDM was not done for all women for study purposes and no
data were available on glucose tolerance before pregnancy.
Further studies are needed to replicate our findings among more
high-risk populations, including women with impaired glucose
tolerance from preconception and early pregnancy onwards and
women at risk to develop GDM. We only measured maternal
glucose levels once in early pregnancy. However, it has been
suggested that impaired glucose control in early pregnancy per-
sists throughout pregnancy [38]. The fasting time before venous
puncture was limited to 30 min, due to which we consider our
samples non-fasting samples. We were not able to collect blood
samples after a longer fasting period due to the design of the
study. The blood samples were collected in a non-fasting state
at different time-points during the day, depending on time of the
study visit. Since glucose levels shift very easily during the day
and are sensitive towards carbohydrate intake, this may have led
to non-differential misclassification of what would be classified
as high- or low-glucose levels and an underestimation of the
observed effect estimates. We also did not have information on
1 h and 2 h postprandial glucose levels available. However, it has
been suggested that maternal fasting glucose levels, postprandial
glucose levels and non-fasting random samples are appropriate
measures of maternal glucose metabolism and are related to
adverse birth outcomes [2, 7]. Non-fasting blood values may
better reflect the normal physiological state in pregnant women
[4, 31]. Further studies are needed to replicate our findings using
more detailed maternal glucose measurements, including fasting
glucose levels and detailed postprandial glucose measurements.
Althoughwe includedmany covariates, there still might be some
residual confounding, as in any observational study.
Conclusions
Maternal early-pregnancy non-fasting blood glucose level is as-
sociated with altered fetal growth patterns, characterised by de-
creased fetal growth rates in mid-pregnancy and increased fetal
growth rates from late pregnancy onwards, and an increased risk
of delivering a large-for-gestational-age infant. These associations
are only partly explained by maternal pre-pregnancy BMI.
Instead of targeting maternal glucose metabolism in the second
half of pregnancy as in current clinical practice, future preventive
strategies need to focus on screening for an impaired maternal
glucose metabolism from preconception and early pregnancy
onwards to improve fetal growth and birth outcomes.
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